Study Study design / N Treatment Results
Marinov et al. 200425
RET / 68a
Oral NMP 200 mg bd for ≥ 14 days
Oral NMP administered for average of 21 days. Overall, 88% of patients were discharged from hospital with a healthy pregnancy.
Turgal et al. 201726
OL, RCT / 60b
Oral NMP 400 mg/day for 4 weeks vs No treatment Mean placental volume increased more in oral NMP group vs control group: 336% (67–1077) vs 141% (29–900), p = 0.007. No between-group differences in mean change for gestational sac, amniotic sac, or embryonic volumes. No difference between oral NMP vs control for secondary endpoints including live birth rate (92.9% vs 96.4%, p = 0.55) and mean gestational age at delivery (38.0 ± 2.8 vs 38.5 ± 1.6 weeks, p = 0.46).
Siew et al. 201827
OL, RCT / 118c
Oral NMP 200 mg bd vs Oral DYD 10 mg bd, both for 2 weeks No difference between oral NMP and oral DYD groups for miscarriage rate at ≤16 weeks (10.2% vs 15.2%, p = 0.581). No difference in extent of bleeding at days 4–10: 89.7% of oral NMP recipient vs 96.6% of DYD recipients reported similar/less/resolved bleeding vs baseline, p = 0.272.